| Karl F Stephens, MD | |
|
147 County Rd, Barrington, RI 02806-4586 | |
| (401) 245-1775 | |
| (401) 245-1775 |
| Full Name | Karl F Stephens |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 147 County Rd, Barrington, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356433130 | NPI | - | NPPES |
| RI3946 | Other | EYEMED | |
| 6365 | Other | BCBSRI | |
| 9000636 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | RI3946 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karl F Stephens, MD 147 County Rd, Barrington, RI 02806-4586 Ph: (401) 245-1775 | Karl F Stephens, MD 147 County Rd, Barrington, RI 02806-4586 Ph: (401) 245-1775 |
News Archive
Calcivis, a medical devices company focused on revolutionising the management of tooth decay, today announces that its Calcivis Caries Activity Imaging System has been granted a CE Mark in Europe. A CE Mark is required before a medical device can be marketed in the EU and a number of other countries and signifies that the manufacturer meets the requirements of European legislation.
Fujitsu Laboratories, Ltd. in collaboration with researchers at the University of Toronto (U of T) today announced the development of a technology for dramatically streamlining the creation of radiation treatment plans for Gamma Knife radiosurgery, leveraging Fujitsu's quantum-inspired computing technology, the Digital Annealer, which rapidly solves combinatorial optimization problems.
Scientists at The University of Texas Health Science Center at Houston are on the forefront of stem cell research, developing novel therapies designed to generate heart cells, repair traumatic lung injuries, grow new bone and stanch the spread of cancer cells.
Salix Pharmaceuticals, Ltd. has announced that Salix Pharmaceuticals, Inc. has filed a lawsuit in the United States District Court for the District of New Jersey against Novel Laboratories, Inc. for infringement of the patent protecting OSMOPREP (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets.
Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, announced today that it has entered into a global collaboration with Pfizer Inc. for the development and potential commercialization of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus (AAV) vectors for the potential treatment of hemophilia B.
› Verified 8 days ago
Dr. Kendall A Gibbs, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 24 Bosworth St, Barrington, RI 02806 Phone: 401-247-2015 |